Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis*
暂无分享,去创建一个
[1] S. Lapinsky,et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis* , 2010, Critical care medicine.
[2] Alastair D Hay,et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.
[3] Joshua A. Doherty,et al. Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis , 2010, Antimicrobial Agents and Chemotherapy.
[4] C. Natanson,et al. Bundled care for septic shock: An analysis of clinical trials* , 2010, Critical care medicine.
[5] N. Nesseler,et al. Risk factors for multidrug-resistant bacteria in patients with post-operative peritonitis requiring intensive care. , 2010, The Journal of antimicrobial chemotherapy.
[6] B. Murray,et al. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.
[7] Ricard Ferrer,et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. , 2009, American journal of respiratory and critical care medicine.
[8] François Gouin,et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) , 2009, Critical care medicine.
[9] J. Low,et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore , 2009, European Journal of Clinical Microbiology & Infectious Diseases.
[10] Joshua A. Doherty,et al. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis* , 2009, Critical care medicine.
[11] K. Stellrecht,et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. , 2008, The Journal of antimicrobial chemotherapy.
[12] M. Kollef,et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections* , 2008, Critical care medicine.
[13] M. Kollef. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] M. Levy,et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.
[15] Á. Soriano,et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] M. Kollef,et al. Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience , 2007, Antimicrobial Agents and Chemotherapy.
[17] L. McNutt,et al. Identification of Patients With Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk of Infection With Carbapenem-Resistant Isolates , 2007, Infection Control & Hospital Epidemiology.
[18] Jessina C. McGregor,et al. Clinical Prediction Tool To Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multidrug Resistance , 2006, Antimicrobial Agents and Chemotherapy.
[19] Scott T. Micek,et al. Before–after study of a standardized hospital order set for the management of septic shock* , 2006, Critical care medicine.
[20] M. Falagas,et al. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. , 2006, The Journal of hospital infection.
[21] E. D’Agata,et al. The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies , 2006, Infection Control & Hospital Epidemiology.
[22] W. Bilker,et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. , 2006, The American journal of medicine.
[23] J. Garnacho-Montero,et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.
[24] Stephan Harbarth,et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.
[25] R. Schein,et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results* , 2003, Critical care medicine.
[26] A. Combes,et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] R. Auckenthaler,et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] G. Clermont,et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.
[29] G Sherman,et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.
[30] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[31] Aseem Kumar,et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) , 2010 .
[32] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] Mary Jane Ferraro,et al. Performance standards for antimicrobial susceptibility testing : twelfth informational supplement , 2002 .